Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new paper published on line in the Journal of Urology suggests that the PSA and %free PSA levels of current smokers and former smokers may be statistically significantly impacted compared to those of men who have very rarely or never smoked.
Filed under: Diagnosis, Risk | Tagged: free, history, PSA, smoking, total | 1 Comment »
Members of the Prostate Cancer Roundtable have received a letter from the Agency for Healthcare Research and Quality (AHRQ) addressing issues raised by the Roundtable members about the draft USPSTF recommendations on use of the PSA test in screening for risk of prostate cancer.
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, testing | 2 Comments »
For our US-based readers … It appears that Rep. Kucinich’s statements on his web site (reported on this web site a few days ago) are something of a political simplification of reality.
Filed under: Diagnosis, Risk | Tagged: PSA, recommendation, screening, USPSTF | 1 Comment »
According to an announcement on the web site of Congressmen Dennis Kucinich late yesterday, HHS Secretary Kathleen Sebelius has agreed to overule the draft recommendation issued by the U.S. Preventive Services Task Force (USPSTF) related to the use of PSA testing as a means to detect prostate cancer.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PSA, rfisk, screening, testing | 9 Comments »
A new article in the Canadian Medical Association Journal has reported on a careful analysis of the published literature underlying current guidelines on the use of repetitive PSA testing to monitor risk for progression in men receiving first-line treatment for localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: guideline, monitoring, PSA, recurrence | 3 Comments »
In September last year we provided information about a Danish study by Orsted et al. on the use of PSA levels in projecting the long-term risk of prostate cancer that had been presented at a scientific meeting in Europe.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: baseline, long-term, PSA, risk | 2 Comments »
When Paul VanDervelder was told his PSA had spiked, he did what many men do. He panicked! But then he did what he was trained to do as an investigative journalist. He investigated.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, PSA, risk | 7 Comments »
A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cancer-specific, marker, mortality, neoadjuvant, progression, PSA, radiation, surrogate | 2 Comments »
The October issue of the Canadian Journal of Urology contains an interesting and thorough review of the available data on the value of screening for prostate cancer as seen by a group including urologists, urologic oncologists, medical oncologists, radiation oncologists, and a highly regarded primary care physician.
Filed under: Diagnosis, Risk | Tagged: mortality, PSA, risk, screening, testing | Leave a Comment »
The debate over the merits and risks of widespread screening for prostate cancer using the PSA test is hardly confined to the USA. A new article (in German) in the journal Urologie A addresses exactly the same issues as have recently received so much attention here in the States.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, mortality, PSA, risk, screening | 1 Comment »
It is not exactly “new” news that PSA doubling times calculated using low levels of ultrasensitive PSA data can be very different to those calulated using standard PSA values. However, a new paper has provided some additional data on this issue.
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, PSA, standard, ultasensitive | 3 Comments »
On November 8, the American Urological Asociation (AUA) issued its full, formal comment letter on the US Preventive Services Task Force (USPSTF)’s draft recommendation of a “D” grade for the use of PSA screening in healthy men with no symptoms of prostate cancer. The AUA also issued a formal statement for the media.
Filed under: Diagnosis, Risk | Tagged: AUA, Diagnosis, PSA, risk, screening, USPSTF | 3 Comments »
This week’s issue issue of the New England Journal of Medicine includes four perspective articles on the recent draft recommendation about PSA screening issued by the U.S. Preventive Services Task Force (USPSTF).
Filed under: Diagnosis, Risk | Tagged: PSA, recommendation, screening, testing, USPSTF | 5 Comments »
According to data from a prospective study of prostate cancer outcomes conducted by researchers at the Mayo Clinic, the PSA test is “valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer.”
Filed under: Diagnosis, Management, Risk | Tagged: benefit, biopsy, PSA, risk | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site